1. Part 4
This slide reviews recommendations for antiplatelet therapy from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

2. This slide reviews recommendations for screening and treatment of coronary heart disease from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

3. This slide reviews recommendations for screening and treatment of diabetic neuropathy from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

4. This slide reviews recommendations for screening and treatment of diabetic retinopathy from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

5. This slide reviews recommendations for screening and treatment of diabetic neuropathy from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

6. This slide reviews recommendations for foot care management in diabetes from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January 2014
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

7. This slide reviews recommendations for managing diabetes in older adults from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January 2014
Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

8. This slide reviews recommendations for pharmacologic therapy to treat and manage diabetes in older adults from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January 2014
Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

9. This slide reviews glycemic targets for children and adolescents with type 1 diabetes from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January 2014
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.

10. This slide reviews recommendations for screening for autoimmunities in children and adolescents with type 1 diabetes from the 2015 ADA guidelines.
Refer to source document for full recommendations, including level of evidence rating.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
January 2014
This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.